ADVANCED ENZYME TECH LTD
ADVENZYMES · General/Diversified · NSE
₹361
Current Market Price
Fair Value (DCF)
₹323
Discount to FV
-10.7%
Updated just now
YieldIQ Score
68/100
Piotroski F-Score
7/9
Economic Moat
Wide
Confidence
64%
ROE
10.3%
Debt/Equity
0.02
WACC
11.1%
Market Cap
₹4,047 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
16.5%
Return on capital employed
EV / EBITDA
10.1×
Enterprise multiple
Debt / EBITDA
0.1×
Leverage vs earnings
Interest Coverage
53.6×
EBIT covers interest
Current Ratio
9.09×
Short-term liquidity
Asset Turnover
0.46×
Revenue per ₹ of assets
Revenue CAGR (3Y)
11.3%
3-year revenue growth
Revenue CAGR (5Y)
21.3%
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹361.4
Bear case
Discount -104.5%
Base case
Discount -12.0%
Bull case
Discount +6.7%
Ratio Trends
ADVENZYMES · last 10 annual periods
ROE
10.3%
ROCE
16.5%
Operating Margin
—
Debt / Equity
0.02×
PE
16.9×
EV / EBITDA
10.1×
Historical Financials
ADVENZYMES · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2022 NSE_XBRL | 2023 NSE_XBRL | 2024 NSE_XBRL | 2025 yfinance | 2026 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹529 Cr | ₹540 Cr | ₹623 Cr | ₹637 Cr | ₹746 Cr | +9.0% |
| EBITDA | ₹208 Cr | ₹178 Cr | ₹226 Cr | ₹227 Cr | ₹275 Cr | +7.3% |
| EBIT | ₹173 Cr | ₹143 Cr | ₹191 Cr | — | — | +2.5% |
| PAT | ₹120 Cr | ₹106 Cr | ₹133 Cr | ₹131 Cr | ₹169 Cr | +9.0% |
| EPS (diluted) | ₹10.68 | ₹9.45 | ₹11.92 | — | — | +2.8% |
| CFO | ₹122 Cr | ₹140 Cr | ₹141 Cr | ₹142 Cr | ₹157 Cr | +6.4% |
| CapEx | ₹-28.2 Cr | ₹-38.2 Cr | ₹-47.3 Cr | ₹-34.8 Cr | ₹-52.4 Cr | — |
| FCF | ₹94.1 Cr | ₹102 Cr | ₹94.1 Cr | ₹108 Cr | ₹104 Cr | +2.6% |
| Total Assets | ₹1268 Cr | ₹1422 Cr | ₹1535 Cr | ₹1621 Cr | ₹1839 Cr | +9.7% |
| Total Debt | ₹34.7 Cr | ₹33.5 Cr | ₹47.3 Cr | ₹39.4 Cr | ₹32.0 Cr | -2.0% |
| Shareholders' Equity | ₹1089 Cr | ₹1235 Cr | ₹1324 Cr | ₹1421 Cr | ₹1632 Cr | +10.7% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
ADVENZYMES vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
 LXCHEM LXCHEM | — | — | Pending | 4.0% | 37.8× |
POCL POCL | — | — | Pending | 9.8% | — |
VISHNU VISHNU | — | — | Pending | 13.7% | — |
PREMEXPLN PREMEXPLN | — | — | Pending | 11.6% | — |
FCL FCL | — | — | Pending | 12.3% | 20.6× |
Click a ticker to view its fair-value analysis.
Dividend History
12 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹17.20/sh
Last payout
2025-07-23
₹1.20
Peak payout
₹4.00
Trailing yield
0.33%
Amounts parsed from NSE subject lines. Percent-of-face-value declarations are converted using the per-ticker face value (defaults to ₹10).
AI Analysis Summary
Model-generated description of metrics. Not investment advice. ADVANCED ENZYME TECH LTD (ADVENZYMES.NS) trades at 361.40 vs a model fair value of 322.63, a gap of -10.7%. Piotroski F-score: 7/9. Moat ...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of ADVENZYMES →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for ADVENZYMES →
Compare
Head-to-head with peers
Compare ADVENZYMES side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse ADVENZYMESNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.